FUNDAMENTALS · Fundamentals · KY Healthcare

Tanvex BioPharma (6541) Fundamentals 2026 — Revenue Analysis | SniperIQ

Tanvex BioPharma (6541) is a KY-listed Healthcare company in Biotechnology with a market capitalization of NT

0.6B, trading at NT$40.00 on the TAI. This SniperIQ fundamentals page covers Tanvex BioPharma's valuation, profitability (net margin -294.1%), revenue (NT$401M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market CapNT
0.6B
Net Margin-294.1%
Revenue (FY25)NT$401M

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Tanvex BioPharma's market cap?

Tanvex BioPharma (6541) has a market capitalization of approximately NT

0.6B, trading at NT$40.00 on the TAI. Market cap moves with the live share price.

What is Tanvex BioPharma's P/E ratio?

Tanvex BioPharma's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 2.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Tanvex BioPharma?

Tanvex BioPharma runs a net profit margin of -294.1%, a gross margin of -159.4%, and an operating margin of -288.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Tanvex BioPharma generate?

Tanvex BioPharma reported revenue of NT$401M for fiscal year 2025, with net income of -NT

.5B and earnings per share (EPS) of -6.13. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Tanvex BioPharma pay a dividend?

Tanvex BioPharma does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Tanvex BioPharma financially healthy?

Tanvex BioPharma carries a debt-to-equity ratio of 0.31x and a current ratio of 1.33x, with a market beta of 0.21. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Tanvex BioPharma a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Tanvex BioPharma (6541) the key facts are: market cap NT

0.6B, revenue NT$401M, 52-week range 37.3-68. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Tanvex BioPharma's full fundamentals live

Get Tanvex BioPharma's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: HBM Holdings (2142) fundamentals · Dallah Healthcare (4004) fundamentals · Charles River Laboratories International (CRL) fundamentals · Yantai Dongcheng Pharmaceutical Group (002675) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons